Yevgeniy Samyshkin, MSc

Director, Economic Modelling and Research Analytics
Value Evidence and Outcomes, GlaxoSmithKline, United Kingdom

Poster(s):

• (306) Life-year and quality-adjusted life-year results from a United States cost-effectiveness model for belantamab mafodotin, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma
  Wednesday, October 29, 2025

• (311) Belantamab Mafodotin Individual Patient Dosing in Patients With Relapsed/Refractory Multiple Myeloma Treated in the Phase 3 DREAMM-7 and DREAMM-8 Clinical Trials
  Wednesday, October 29, 2025